性别对类风湿关节炎患者阿巴西普治疗反应与耐受性的影响:ORA注册研究结果
基于ORA注册研究990例接受阿巴西普治疗的类风湿关节炎患者,评估性别对疗效与耐受性的影响。经多因素校正后,男女在缓解率与EULAR应答方面无差异,女性随访期间DAS28与压痛关节数持续较高,但药物留存率与安全性相当。
要点
- 校正混杂因素后,男女阿巴西普治疗缓解率无差异。
- 男女EULAR良好或中度应答比例相似(52.4% vs 55.5%)。
- 女性随访期DAS28与压痛关节数持续高于男性,但药物留存与安全性相当。
核心结论
- 在已确诊类风湿关节炎的日常实践队列中,女性接受阿巴西普治疗获得的缓解与EULAR应答与男性相似。
- 尽管女性基线及随访期间疾病活动度和压痛关节数更高,药物留存与安全性在男女间相当。
研究设计与样本
- 基于ORA(Orencia and Rheumatoid Arthritis)注册研究的前瞻性队列分析。
- 从1017例患者中纳入990例至少有一次随访访视者,女性占79.3%,随访2年。
- 在基线、6、12、24个月评估疾病活动度,多因素分析探索性别与EULAR应答、DAS28缓解及不良事件的关系。
主要发现
- 基线时女性病程更长、疾病活动度更高、更多使用过抗TNF药物。
- 校正年龄、病程、活动度、RF与抗CCP阳性、当前DMARDs、既往TNF阻滞剂及糖皮质激素使用后,随访期间男女缓解率无差异。
- 男女在任何终点达到EULAAR良好或中度应答的比例相似(52.4% vs 55.5%),达到EULAR应答的时间也相似(5.4±4.9 vs 5.6±5.2个月)。
- 女性在6个月时中度EULAR应答更常见(OR=1.80,p=0.02),但12或24个月时不再显著。
- 随访期间女性DAS28、压痛关节计数评分和患者总体评估持续较高(p分别为0.001、0.04和0.06)。
关键数值与推荐
- 男女EULAR良好或中度应答比例分别为52.4%与55.5%。
- 达到EULAR应答时间男女分别为5.4±4.9与5.6±5.2个月。
- 女性6个月中度EULAR应答OR=1.80,p=0.02。
- 随访期女性DAS28、压痛关节计数与患者总体评估的p值分别为0.001、0.04和0.06。
临床怎么用
- 临床中不应因性别差异而限制阿巴西普在女性类风湿关节炎患者中的使用。
- 女性患者尽管报告更高的疾病活动度和压痛关节数,仍可获得与男性相似的缓解和EULAR应答。
- 阿巴西普的药物留存与安全性在男女间相当,支持在女性中持续治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The impact of gender on the response and tolerance to abatacept was assessed in a large prospective cohort during 2 years of follow-up. METHODS: From the 1017 patients included in the Orencia and Rheumatoid Arthritis registry, disease activity was assessed at baseline, 6, 12 and 24 months. The relationship between the European League Against Rheumatism (EULAR) response, Disease Activity Score 28 (DAS28) remission, rate of adverse events and gender was explored in multivariate analysis. RESULTS: 990 patients, 79.3%female, with at least one follow-up visit were analysed. At baseline, women had longer disease duration, higher disease activity and more often received antitumour necrosis factor (TNF) drugs. The remission was not different between men and women during the follow-up after adjustment on age, disease duration and activity, rheumatoid factor and anti-cyclic citrullinated pyeptide (CCP) positivity, and current disease-modifying antirheumatic drugs (DMARDs), previous TNF blockers and corticosteroids use. The proportion of men and women achieving EULAR good-or-moderate response at any endpoints was similar (52.4% vs 55.5%), as well as time to achieving EULAR response (5.4±4.9 vs 5.6±5.2 months). Moderate EULAR response was more frequent in women at 6 months (OR=1.80, p=0.02) but was no longer significant at 12 or 24 months. During the follow-up, the DAS28, the tender joint count score and the patient global assessment remained higher in women (p=0.001, 0.04 and 0.06, respectively). Drug retention and safety were comparable. CONCLUSION: In this large daily practice cohort of established rheumatoid arthritis treated with abatacept, women achieved similar remission and EULAR response than men despite higher disease activity and tender joint count during the treatment course.
引用
- Nourisson C, Soubrier M, Mulliez A, et al. Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry. RMD Open. 2017. PMID: 29177081. doi:10.1136/rmdopen-2017-000515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。